drugset / Trial / NCT00730964

A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.

NCT00730964

Phase 4 Completed 1039 enrolled GE Healthcare
NaSingle-groupOpen-label

Summary

This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.

Timeline

Start
2008-05
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Optison Diagnostic / imaging agent 0.5 ml Intravenous

Indications

No indication recorded.